ReviewAnnals of the New York Academy of Sciences2013
New paradigms for treatment-resistant depression.
Review in Annals of the New York Academy of Sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 110 citations in OpenAlex.
- Group-Based Symptom Trajectory of Intramuscular Administration of Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder: A Post-Hoc Analysis.Neuropsychiatric disease and treatment · 2023Trial
- Treatment response to bupropion: an investigation of changes in resting-state functional connectivity in patients with major depressive disorder.Psychopharmacology · 2026Article
- Article
- Article
- A unique case of very low-dose subcutaneous ketamine use: Maintenance option of ketamine for treatment-resistant depression.Clinical case reports · 2022Article
- Article
- Novel drug developmental strategies for treatment-resistant depression.British journal of pharmacology · 2022Review
- Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial.Frontiers in psychiatry · 2022Article
- Unfolding the Role of BDNF as a Biomarker for Treatment of Depression.Journal of molecular neuroscience : MN · 2021Review
- Low Doses of Ketamine and Melatonin in Combination Produce Additive Antidepressant-like Effects in Mice.International journal of molecular sciences · 2021Article
- Treatment-Resistant Depression Revisited: A Glimmer of Hope.Journal of personalized medicine · 2021Review
- Nutrition and behavioral health disorders: depression and anxiety.Nutrition reviews · 2021Review
- Isolation and Synthesis of Veranamine, an Antidepressant Lead from the Marine SpongeJournal of natural products · 2020Article
- NLRP1-Mediated Antidepressant Effect of Ketamine in Chronic Unpredictable Mild Stress Model in Rats.Psychiatry investigation · 2020Article
- Biomarkers in Drug Free Subjects with Depression : Correlation with Tryptophan.Psychiatry investigation · 2019Article
- The Role of BDNF in the Neuroimmune Axis Regulation of Mood Disorders.Frontiers in neurology · 2019Review
- Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.Journal of child and adolescent psychopharmacology · 2018Article
- Exploring Nitrous Oxide as Treatment of Mood Disorders: Basic Concepts.Journal of clinical psychopharmacology · 2018Review
- Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.Psychopharmacology · 2018Article
- Clinical significance of interleukin‑6 and inducible nitric oxide synthase in ketamine‑induced cystitis.International journal of molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 6 institutions in 5 countries.
Funding
Abstract
Clinical depression is a serious mental disorder characterized by low mood, anhedonia, loss of interest in daily activities, and other symptoms, and is associated with severe consequences including suicide and increased risk of cardiovascular events. Depression affects nearly 15% of the population. The standard of care for the last 50 years has focused on monoamine neurotransmitters, including such treatments as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). However, these treatments have significant limitations: they can take weeks before showing mood-altering effects, and only one to two out of ten patients shows clinical effects beyond those associated with placebo. A major paradigm shift in research into the treatment of depression is underway, based on promising results with the glutamatergic NMDA receptor antagonist ketamine. Further research has demonstrated the significance of glutamatergic pathways in depression and the association of this system with the stress pathway and magnesium homeostasis. Treatment with NMDA receptor antagonists and magnesium have shown the ability to sprout new synaptic connections and reverse stress-induced neural changes, opening up promising new territory for the development of drugs to meet the unmet need in patients with clinical depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.